
<!DOCTYPE html>
<html lang="en">
<head>
<!-- Meta-Tag -->
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">

<title>TolsuraHCP</title>

<meta name="apple-mobile-web-app-status-bar-style" content="#cd9f26">
<meta name="theme-color" content="#cd9f26" />

<!-- googlefont -->
<link rel="preconnect" href="https://fonts.gstatic.com">
<link href="https://fonts.googleapis.com/css2?family=Source+Sans+Pro:ital,wght@0,400;0,600;0,700;1,400;1,600;1,700&display=swap" rel="stylesheet">

<!-- favicon -->
<link rel="icon" href="assets/img/favicon.ico">

<!-- CSS -->
<link rel="stylesheet" href="assets/css/bootstrap.min.css">
<link rel="stylesheet" href="assets/css/style.css">
</head>
<body>
<!-- Announcement Bar Start -->
<div class="announcement__bar text-center text-white pt-lg-3 pb-lg-3 pt-2 pb-2">
    <div class="container">
        <div class="d-flex justify-content-center align-items-center">
            <div class="announcement__title"><strong>JOIN US FOR A SPECIAL WEBINAR</strong> ABOUT OUR BREAKTHROUGH ANTIFUNGAL INNOVATION, TOLSURA</div>
            <a href="#" class="btn btn-transparent"><span class="d-none d-lg-block">REGISTER TO JOIN</span><img class="d-block d-lg-none" src="assets/img/icons-arrow_right.svg" alt="Icons Arrow Right"> </a>
        </div>
    </div>
</div>
<!-- Announcement Bar End -->

<!-- HEADER START -->
<header>
    <div class="container">
        <div class="d-flex align-items-center">
            <a class="nav__toggle" href="#" aria-label="Toggle navigation"><span>&nbsp;</span><span>&nbsp;</span><span>&nbsp;</span></a>
            <a href="index.html" class="logo"><img src="assets/img/TOLSURA_DARK_LOGO.png" alt="Go To Tolsura"></a>
            <div class="nav__block flex-column">
                <div class="nav-wrapper d-flex flex-lg-column-reverse">
                    <div class="primary__nav">
                        <ul>
                            <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="infection-overview.html">INFECTIONS OVERVIEW</a></li>
                            <li class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item current_page_item"><a href="#">ABOUT TOLSURA</a></li>
                            <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children"><a href="#">BENEFITS OF TOLSURA</a>
                                <ul>
                                    <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="bioavailability.html">BIOAVAILABILITY</a></li>
                                    <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="absorption.html">ABSORPTION</a></li>
                                    <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="therapeutic-levels.html">THERAPEUTIC LEVELS</a></li>
                                </ul>
                            </li>
                            <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="safety.html">SAFETY</a></li>
                            <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="dosing.html">DOSING</a></li>
                            <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="savings.html">SAVINGS</a></li>
                        </ul>
                    </div>
                    <div class="secondary__nav mb-md-3">
                        <ul>
                            <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="#isi-expand">Important Safety Information</a></li>
                            <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="#">Prescribing Information</a></li>
                            <li class="menu-item menu-item-type-post_type menu-item-object-page"><a href="#">Patient Site</a></li>
                        </ul>
                    </div>
                </div>
            </div>
            <div class="ml-auto">
                <a class="btn" data-toggle="modal" data-target="#myModal">Contact A Representative</a>
            </div> 
        </div>
    </div>
</header>
<!-- HEADER END -->

<!-- BANNER SECTION START -->
<section class="page__banner" style="background-image: url(assets/img/Suba_technology_triangle_graphic.png);">
    <div class="container">
        <div class="page__banner-description">
            <h1>Advanced Antifungal Delivery Technology</h1>
            <p><strong>With its game-changing SUBA® technology</strong>, TOLSURA is an evolution in anti-fungal therapy that provides a treatment course for your patients unlike any other itraconazole formulation.</p>
            <div class="btn-row">
                <a href="#" class="btn" data-toggle="modal" data-target="#myVideo">PLAY MECHANISM OF ACTION VIDEO</a>
            </div>
        </div>
    </div>
</section>
<div class="modal" id="myVideo">
    <div class="modal-dialog video modal-dialog-centered">
      <div class="modal-content">
        <button type="button" class="close" data-dismiss="modal"><img src="assets/img/Icons_close-white.svg" alt="close"></button>
        <div class="modal-body">
            <script src="https://fast.wistia.com/embed/medias/jqf8u63qgs.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_jqf8u63qgs videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/jqf8u63qgs/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" aria-hidden="true" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
        </div>
      </div>
    </div>
  </div>
<!-- BANNER SECTION END -->

<!-- skip to content link start -->
<a class="sr-only skip-link screen-reader-text" href="#maincontent">Skip to the content</a>
<!-- skip to content link end -->

<!-- PAGE CONTENT START -->
<main id="maincontent" class="pagecontent">
  
  <!-- SUBA-TECHNOLOGY SECTION START -->
  <div class="section suba__pill__technology lazyload pt-100" data-bgset="assets/img/pill-video-screenshot-mobile.png [(max-width: 767px)] | assets/img/pill-video-screenshot.png">
    <div class="container">
        <h2><strong>SUBA® technology delivers approximately double the bioavailability</strong> of conventional 100 mg itraconazole capsules in a smaller 65 mg dose<sup>1</sup>. This breakthrough innovation enhances the solubility and absorption of poorly soluble drugs such as conventional itraconazole<sup>1</sup>.</h2>
    </div>
    <div class="note-text"><p>(Size of capsules in image do not reflect actual TOLSURA capsules size.)</p></div>
  </div>
  <!-- SUBA-TECHNOLOGY SECTION END -->

  <!-- SUBA-TECHNOLOGY SECTION START -->
  <div class="section suba__technology pt-100 pb-100">
    <div class="primary__title">
        <div class="container">
          <h2>WHAT IS SUBA® TECHNOLOGY?</h2>
        </div>
    </div>
    <div class="suba__technology-feature mt-md-5">
        <div class="container">
            <div class="row">
                <div class="col-lg-6">
                    <div class="feature-wrapper d-flex">
                        <div class="feature__icon"><img src="assets/img/nanoparticles_icon.svg" alt="THE SCIENCE OF SUBA"></div>
                        <div class="feature__description">
                            <h3><strong>THE SCIENCE OF SUBA®</strong></h3>
                            <p><strong>The novel SUBA® process utilizes a unique spray-drying technology</strong> which combines the drug and a polymer solution to generate an amorphous solid dispersion powder.</p>
                            <p>This produces microencapsulated nanoparticles of itraconazole dispersed in a polymer matrix, instead of the conventional crystalline form.</p>
                        </div>
                    </div>
                </div>
                <div class="col-lg-6">
                    <div class="feature-wrapper d-flex">
                        <div class="feature__icon"><img src="assets/img/soluble-icon.svg" alt="CONVENTIONAL ITRACONAZOLE"></div>
                        <div class="feature__description">
                            <h3><strong>UNLIKE CONVENTIONAL ITRACONAZOLE,</strong></h3>
                            <p>TOLSURA is less soluble in the acidic environment of the stomach and soluble in the higher pH of the small intestine, resulting in improved absorption<sup>2</sup>.</p>
                        </div>
                    </div>
                </div>
            </div>
            <div class="infection__card pt-100">
                <div class="row align-items-center pb-100">
                    <div class="col-lg-5">
                        <div class="card__wrapper">
                            <img class="triangle" src="assets/img/Triangle-gray.svg" alt="Traingle Gray">
                            <div class="card__img position-relative">
                                <img class="img-fluid" src="assets/img/Crystalline-Itraconazole.png" alt="Crystalline Itraconazole">
                            </div>
                            <div class="card__description gray__bg d-flex justify-content-between">
                                <div class="card__title">
                                    <p>Crystalline itraconazole</p>
                                </div>
                            </div>
                        </div>
                    </div>
                    <div class="col-lg-7">
                        <div class="region__img mt-lg-0 mt-5">
                            <img class="img-fluid" src="assets/img/graph-1-2x.png" alt="Conventional Itraconazole">
                        </div>
                    </div>
                </div>
                <div class="row align-items-center">
                    <div class="col-lg-5">
                        <div class="card__wrapper">
                            <img class="triangle" src="assets/img/Triangle-gray.svg" alt="Traingle Gray">
                            <div class="card__img position-relative">
                                <img class="img-fluid" src="assets/img/Suba-Itraconazole.png" alt="Suba Itraconazole Solid Dispersion">
                            </div>
                            <div class="card__description green__bg d-flex justify-content-between">
                                <div class="card__title">
                                    <p>SUBA® itraconazole solid dispersion</p>
                                </div>
                            </div>
                        </div>
                    </div>
                    <div class="col-lg-7">
                        <div class="region__img mt-lg-0 mt-5">
                            <img class="img-fluid" src="assets/img/graph-2-2x.png" alt="SUBA Itraconazole">
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>
  </div>
  <!-- SUBA-TECHNOLOGY SECTION END -->

  <!-- TOLSURA-FINDINGS SECTION END -->
  <div class="section tolsura__findings pt-100 pb-md-5">
    <div class="primary__title">
        <div class="container">
            <div class="row">
                <div class="col-xl-9 col-lg-8">
                    <h2>TOLSURA TAKES ON CONVENTIONAL ITRACONAZOLE<sup>3</sup></h2>
                </div>
            </div>
        </div>
    </div>
    <div class="title-col mb-5">
        <div class="container">
            <h3>INTERIM FINDINGS</h3>
            <p>Pharmacokinetic results to Day 42 of treatment from a head-to-head clinical trial</p>
        </div>
    </div>
    <div class="tolsura__findings-list pt-md-5">
        <div class="container">
            <div class="row">
                <div class="col-lg-4">
                    <div class="list__wrapper border-right">
                        <h4><strong>TOLSURA SHOWS LESS PATIENT VARIABILITY</strong> than conventional itraconazole<sup>1</sup> <em>(Figure)</em></h4>
                        <ul>
                            <li>N=2 patients with high exposure in the TOLSURA group received dose reductions</li>
                        </ul>
                    </div>  
                </div>
                <div class="col-lg-4">
                    <div class="list__wrapper border-right">
                        <h4>10% of conventional itraconazole patients had not achieved therapeutic levels of itraconazole by Day 42; <strong>100% of TOLSURA patients were above the therapeutic threshold</strong><sup>3</sup></h4>
                    </div>
                </div>
                <div class="col-lg-4">
                    <div class="list__wrapper">
                        <h4><strong>TOLSURA was safe and well tolerated</strong><sup>3</sup></h4>
                        <ul>
                            <li>50% less gastrointestinal events in the TOLSURA group (13%) than the conventional itraconazole group (26%)</li>
                            <li>Low rate of abnormal LFTs in both treatment groups</li>
                        </ul>
                    </div>
                </div>
            </div>
        </div>
    </div>
  </div>
  <!-- TOLSURA-FINDINGS SECTION END -->

  <!-- TOLSURA-STUDY SECTION START -->
  <div class="section tolsura__study pt-100 pb-100">
    <div class="d-flex align-items-center flex-lg-row flex-column">
        <div class="tolsura__study-article gray__bg mb-lg-0 mb-5">
            <h2>STUDY DESIGN</h2>
            <div class="study-article-list">
                <ul>
                    <li>
                        Subjects with endemic mycoses (including but not limited to histoplasmosis, blastomycosis) who have had &lt;14 days of prior antifungal therapy
                        <ul>
                            <li>Life-threatening or CNS disease excluded</li>
                        </ul>
                    </li>
                    <li>
                        A prospective, multi-center, randomized, open-label parallel arm study
                        <ul>
                            <li>TOLSURA 130 mg PO BID after 3-day loading dose (130mg PO TID)</li>
                            <li>Sporanox, supplied as generic itraconazole capsules (Patriot), 200 mg PO BID after 3-day loading dose (200mg PO TID)</li>
                        </ul>
                    </li>
                    <li>Clinical Assessments: <br>Days 7, 14, 28, 42, 84, 180</li>
                    <li>Pharmacokinetics: <br>Days 7, 14, 42</li>
                </ul>
            </div>
        </div>
        <div class="article__right">
            <div class="article__img">
                <img class="img-fluid mb-4" src="assets/img/Intrapatient-variability-graph.png" alt="Intrapatient Variability Graph">
            </div>
            <p>To date, pharmacokinetic data is available through Day 42 of treatment (N=51; histoplasmosis or blastomycosis patients). Blood serum levels of itraconazole and hydroxyitraconazole were measured on Days 7, 14 and 42 and plotted to compare the variability among patients. All patients in both treatment arms were initiated with a loading dose. As expected, dosing adjustments were needed in some patients especially at the start of therapy.</p> 
            <p>At each timepoint, and by day 42, interpatient variability is less with TOLSURA than with conventional itraconazole.</p>
        </div>
    </div>
  </div>
  <!-- TOLSURA-STUDY SECTION END -->

  <!-- TOLSURA-HELP SECTION START -->
  <div class="section tolsura__help pt-100 pb-5">
    <div class="header__section" style="background-image: url(assets/img/fatherson-triangle-graphic.png);">
        <div class="primary__title">
            <div class="container">
                <div class="row">
                    <div class="col-xl-7 col-lg-8">
                        <h2>WHAT DOES THIS MEAN FOR YOUR PATIENTS?</h2>
                        <p>High variability in the absorption of conventional itraconazole formulations can result in varying levels of safety and efficacy if dosing is not managed on an individual basis<sup>4</sup>.</p>
                    </div>
                </div>
            </div>
        </div>
    </div>
    <div class="tolsura__help-list">
        <div class="container">
            <h3>TOLSURA WITH SUBA® TECHNOLOGY CAN HELP.<span class="d-block">HERE’S HOW:</span></h3>
            <ul>
                <li><strong>TOLSURA IS UP TO 90% BIOAVAILABLE</strong> with
                    improved overall absorption of conventional
                    itraconazole and consistent plasma levels <sup>1</sup>
                </li>
                <li>
                    <strong>ACHIEVING THERAPEUTIC LEVELS<sup>5,6</sup>:</strong>
                    <div class="d-flex text-center flex-md-row flex-column mt-5">
                        <div class="pie-chart">
                            <img class="img-fluid mb-3" width="200" height="200" src="assets/img/Tolsura-Subject-Chart.svg" alt="Tolsura 65mb Subjects">
                            <div class="chart__title green-color">of TOLSURA 65 mg subjects*</div>
                        </div>
                        <p>COMPARED TO JUST</p>
                        <div class="pie-chart">
                            <img class="img-fluid mb-3" width="200" height="200" src="assets/img/Tolsura-Conventional-Chart.svg" alt="Tolsura 100mg Subjects">
                            <div class="chart__title gray-color">of conventional 100 mg subjects</div>
                        </div>
                    </div>
                    <p>*This difference represents the percentage of subjects in a steady-state PK study above the geometric mean of the conventional itraconazole plasma trough level (1,034 ng/mL)</p>
                </li>
            </ul>
            <ul>
                <li><strong>WITH TOLSURA THERAPEUTIC LEVELS ARE ACHIEVED AND MAINTAINED</strong> in both fed and
                    fasted conditions<sup>7</sup>
                    <p>(FDA dosing instructions require taking TOLSURA with food)</p>
                </li>
                <li>
                    <strong>THE ABSORPTION OF TOLSURA IS NOT REDUCED</strong>† with proton pump inhibitors as the
                    drug is released in the small intestine<sup>5,7,8</sup>
                    <p>†Monitor for side effects as dosing with a proton pump inhibitor may increase peak and overall exposure of itraconazole</p>
                </li>
                <li>
                    <strong>TOLSURA DELIVERS CONSISTENT BLOOD LEVELS OF ITRACONAZOLE</strong> for lower patient
                    variability<sup>2,5</sup>
                </li>
            </ul>
        </div>
    </div>
  </div>
  <!-- TOLSURA-HELP SECTION END -->

  <!-- TOLSURA-TARGET SECTION START -->
  <div class="section green__bg tolsura__target position-relative">
    <img class="traingle-marker img-fluid" src="assets/img/triangle.svg" alt="Traingle Marker">
    <div class="container">
        <h2>TOLSURA — RIGHT ON TARGET</h2>
        <h3>Learn about TOLSURA’s efficacy</h3>
        <div class="row">
            <div class="col-lg-4">
                <a href="bioavailability.html" class="navigation__link">
                    BIOAVAILABILITY
                </a>
            </div>
            <div class="col-lg-4">
                <a href="absorption.html" class="navigation__link">
                    ABSORPTION
                </a>
            </div>
            <div class="col-lg-4">
                <a href="therapeutic-levels.html" class="navigation__link">
                    THERAPEUTIC LEVELS
                </a>
            </div>
        </div>
    </div>
  </div>
  <!-- TOLSURA-TARGET SECTION END -->
  <div class="section absorption position-relative" style="background-image: url(assets/img/Bottle-zoom.png);"><img class="img-fluid absorption-triangle" src="assets/img/suba-technology-triangle-graphic.png" alt="Suba Technology"></div>

  <!-- Contact Modal -->
  <div class="modal" id="myModal">
    <div class="modal-dialog modal-lg">
      <div class="modal-content p-4">
        <!-- Modal Header -->
        <div class="modal-header">
          <button type="button" class="close" data-dismiss="modal"><img src="assets/img/Icons_close.svg" alt="close"></button>
          <div class="form-title" id="form-title">
             INTERESTED IN STARTING YOUR JOURNEY WITH TOLSURA?
             <span class="form-sub-title">
                Sign up for an introductory conversation with one of our representatives
             </span>
          </div>
        </div>
        
        <!-- Modal body -->
        <div class="modal-body">
           <form id="contact-form-popup" method="post">
             <div class="container">
                <div class="row">
                   <div class="col-md-6">
                      <div class="form-group">
                         <label for="firstname">First and Last Name*</label>
                         <input type="text" class="form-control" id="firstname" name="firstname" required="required">
                       </div>
                   </div>
                   <div class="col-md-6">
                      <div class="form-group">
                         <label for="phone">Phone*</label>
                         <input type="text" pattern="[0-9]{1}[0-9]{9}" class="form-control" id="phone"  name="phone" required="required">
                       </div>
                   </div>
                   <div class="col-md-6">
                      <div class="form-group">
                         <label for="jobtitle">Job Title*</label>
                         <div class="controlselect">
                             <select name="jobtitle" id="jobtitle" class="form-control" required="required">
                                 <option value="" selected disabled>Please select</option>
                                 <option value="Doctor of Medicine">Doctor of Medicine</option>
                                 <option value="Doctor of Osteopathy">Doctor of Osteopathy</option>
                                 <option value="Nurse Practitioner">Nurse Practitioner</option>
                                 <option value="Physician Assistant">Physician Assistant</option>
                                 <option value="Medical Assistant">Medical Assistant</option>
                                 <option value="Admin">Admin</option>
                                 <option value="Other">Other</option>
                             </select>
                         </div>
                       </div>
                   </div>
                   <div class="col-md-6">
                      <div class="form-group">
                         <label for="address">Address*</label>
                         <input type="text" class="form-control" id="address"  name="address" required="required">
                       </div>
                   </div>
                   <div class="col-md-6">
                      <div class="form-group">
                         <label for="specialty">Specialty*</label>
                         <div class="controlselect">
                             <select name="specialty" id="specialty" class="form-control" required="required">
                               <option value="" selected disabled>Please select</option>
                               <option value="Infectious Disease">Infectious Disease</option>
                               <option value="Pulmonary Disease">Pulmonary Disease</option>
                               <option value="Internal Medicine">Internal Medicine</option>
                               <option value="Family Medicine">Family Medicine</option>
                               <option value="Hematology/Oncology">Hematology/Oncology</option>
                               <option value="Other">Other</option>
                             </select>
                         </div>
                       </div>
                   </div>
                   <div class="col-md-6">
                      <div class="form-group">
                         <label for="city">City*</label>
                         <input type="text" class="form-control" id="city"  name="city" required="required">
                       </div>
                   </div>
                   <div class="col-md-6">
                      <div class="form-group">
                         <label for="email">Email*</label>
                         <input type="email" class="form-control" id="email"  name="email" required="required">
                       </div>
                   </div>
                   <div class="col-md-6">
                      <div class="row">
                         <div class="col-md-6">
                            <div class="form-group">
                               <label for="zip">ZIP*</label>
                               <input type="text" class="form-control" id="zip"  name="zip" required="required">
                             </div>
                         </div>
                         <div class="col-md-6">
                            <div class="form-group">
                               <label for="state">State*</label>
                               <div class="controlselect">
                                 <select name="state" id="state" class="form-control" required="required">
                                     <option value="" selected disabled>Please select</option>
                                       <option value="CA">California</option>
                                       <option value="CO">Colorado</option>
                                       <option value="CT">Connecticut</option>
                                       <option value="DC">Washington DC</option>
                                       <option value="DE">Delaware</option>
                                       <option value="FL">Florida</option>
                                       <option value="GA">Georgia</option>
                                       <option value="IA">Iowa</option>
                                       <option value="ID">Idaho</option>
                                       <option value="IL">Illinois</option>
                                       <option value="IN">Indiana</option>
                                       <option value="KS">Kansas</option>
                                       <option value="KY">Kentucky</option>
                                       <option value="LA">Louisiana</option>
                                       <option value="MA">Massachusetts</option>
                                       <option value="MD">Maryland</option>
                                       <option value="ME">Maine</option>
                                       <option value="MI">Michigan</option>
                                       <option value="MN">Minnesota</option>
                                       <option value="MO">Missouri</option>
                                       <option value="MS">Mississippi</option>
                                       <option value="MT">Montana</option>
                                       <option value="NC">North Carolina</option>
                                       <option value="ND">North Dakota</option>
                                       <option value="NE">Nebraska</option>
                                       <option value="NH">New Hampshire</option>
                                       <option value="NJ">New Jersey</option>
                                       <option value="NM">New Mexico</option>
                                       <option value="NV">Nevada</option>
                                       <option value="NY">New York</option>
                                       <option value="OH">Ohio</option>
                                       <option value="OK">Oklahoma</option>
                                       <option value="OR">Oregon</option>
                                       <option value="PA">Pennsylvania</option>
                                       <option value="RI">Rhode Island</option>
                                       <option value="SC">South Carolina</option>
                                       <option value="SD">South Dakota</option>
                                       <option value="TN">Tennessee</option>
                                       <option value="TX">Texas</option>
                                       <option value="UT">Utah</option>
                                       <option value="VA">Virginia</option>
                                       <option value="VT">Vermont</option>
                                       <option value="WA">Washington</option>
                                       <option value="WI">Wisconsin</option>
                                       <option value="WV">West Virginia</option>
                                       <option value="WY">Wyoming</option> 
                                     </select>
                               </div>
                             </div>
                         </div>
                      </div>
                      
                   </div>
                </div>
                <div class="row mt-4">
                   <div class="col-md-4 btn-warning-popup">
                      <img src="https://awareness.tolsura.com/l/153741/2021-01-20/43dkgf/153741/16111229975pdGm9Jm/warning_icon.svg" alt="warning"> This is a required field.
                   </div>
                   
                   <div class="col-md-8  text-right">
                      <span class="btn-info-popup">By clicking ‘Send' you agree to be contacted by phone by a sales representative of Mayne Pharma</span>
                      <button class="btn green-btn" onclick="formSubmit()">SEND NOW</button>
                   </div>
                </div>
             </div>
            </form>
            <!--For Thank you Part-->
            <div class="thank-you-popup text-center " id="thankyouPage">
                <div class="thank-you-msg" id="tymsg">
                    <div class="heading red-color mb-5">Thank You</div>
                    <div class="pt-4">One of our representatives will <br /> get in touch with you soon.</div>
                </div>
            </div>
        </div>
      </div>
    </div>
  </div>
</main>
<!-- PAGE CONTENT END -->

<!-- ISI BLOCK START -->
<div id="isi-expand" class="section pt-100">
    <div class="container pb-100">
        <div class="row">            
            <div class="col-md-12">
                <p>Indications and Important <br class="d-block d-lg-none d-md-none">  Safety Information </p>
                <div class="warning-box">
                <p class="mb-0"><strong>BOXED WARNING</strong> <br /><strong>WARNING: CONGESTIVE HEART FAILURE and DRUG INTERACTIONS</strong></p>
                <ul class="bullet1 mb-1 mt-1">
                <li>» CONGESTIVE HEART FAILURE</li>
                </ul>
                <p class="mb-1 pl-3"><strong>TOLSURA can cause or exacerbate congestive heart failure (CHF). When itraconazole was administered intravenously to healthy human volunteers and dogs, negative inotropic effects were seen. </strong>If signs or symptoms of congestive heart failure occur or worsen during administration of TOLSURA, reassess the benefit and risk of continuing treatment.</p>
                <ul class="bullet1">
                    <li> » DRUG INTERACTIONS</li>
                </ul>
                <ul class="bullet2">
                    <li>Co-administration of certain drugs that are metabolized by human CYP3A4 enzymes are contraindicated with
                    TOLSURA because plasma concentrations of such drugs are increased, which may also increase or prolong both the
                    pharmacologic effects and/or adverse reactions to these drugs.</li>
                    <li>Co-administration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and</li>
                    <li>Co-administration with eligustat is contraindicated in subjects taking strong or moderate CYP2D6 inhibitors. </li>
                    <li>Increased plasma concentrations of some of these drugs caused by co-administration with TOLSURA can lead to QT prolongation and/or ventricular tachyarrhythmias, including occurrences of torsades de pointes, a potentially fatal arrhythmia.</li>
                </ul>
            </div>
        </div>
        <div class="col-md-12">
            <p class="mb-0"><strong>Indications and Usage</strong> </p>
            <p>TOLSURA is an azole antifungal indicated for the treatment of the following fungal infections in <strong>immunocompromised and non-immunocompromised</strong> adult patients:</p>
            <ul class="bullet2 ml-2">
                <li>Blastomycosis, pulmonary and extrapulmonary</li>
                <li>Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and</li>
                <li>Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy </li>
            </ul>
            <p class="mb-0 mb-2 mt-4"><strong>Limitations of Use:</strong></p>
            <p class="mb-0">TOLSURA is not indicated for the treatment of onychomycosis.</p>
            <p class="mb-0">TOLSURA is NOT interchangeable or substitutable with other itraconazole products.</p>
            <p class="mb-0 mb-2 mt-4"><strong>Contraindications</strong></p>
            <p class="mb-0">Co-administration with certain drugs that either affect metabolism of itraconazole or whose metabolism is affected by itraconazole Hypersensitivity to itraconazole</p>
            <p class="mb-0 mb-2 mt-4"><strong>Warnings and Precautions</strong></p>
            <ul class="bullet2 ml-2">
                <li><strong>Hepatotoxicity:</strong> Serious hepatotoxicity, including liver failure and death, were reported with the use of itraconazole. Discontinue treatment if signs of liver dysfunction occur</li>
                <li><strong>Cardiac Dysrhythmias:</strong> Life-threatening cardiac dysrhythmias and/or sudden death have occurred in patients using certain drugs that are metabolized by human CYP450 enzymes concomitantly with oral itraconazole and/or other CYP3A4 inhibitors.</li>
                <li><strong>Peripheral Neuropathy:</strong> This has been reported in patients on long-term therapy with itraconazole. Monitor and promptly evaluate neurologic symptoms </li>
                <li><strong>Hearing loss:</strong> Reversible or permanent hearing loss has been reported in patients. Discontinue treatment if hearing loss occurs </li>
            </ul>
            <p class="mb-0 mb-2 mt-4"><strong>Adverse Reactions</strong></p>
            <p class="mb-4">Most common adverse reactions (incidence ≥ 1%) are nausea, rash, vomiting, edema, headache, diarrhea, fatigue, fever, pruritus, hypertension, abnormal hepatic function, abdominal pain, dizziness, hypokalemia, anorexia, malaise, decreased libido, somnolence, albuminuria, and impotence.</p>
            <p class="mb-4"><strong>To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at <a href="tel:+18448258500">1-844-825-8500</a> or the FDA at 1-800-FDA-1088 or <a target="_blank" href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program"><u>www.fda.gov/medwatch.</u></a></strong></p>
            <p class="mb-0"><strong>For more information, please see full <a class="underline" target="_blank" href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=306352d1-9d5a-49ad-b72d-893b99546861&audience=professional"><u>Prescribing Information and Patient Information Leaflet.</u> </a></strong></p>
        </div>
    </div>
    </div>
    <!-- REFERENCE SECTION START -->
    <div class="section pt-100 pb-100">
        <div class="container">
            <div class="references-block">
                <h2>References:</h2>
                <ul>
                    <li>Data on File. Mayne Pharma, Inc. 2017.</li>              
                    <li>Abuhelwa AY, Foster DJ, Mudge S, Hayes D, Upton RN. Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. Antimicrob Agents Chemother. 2015;59(9):5681-5696. doi:10.1128/AAC.00973-15.</li>
                    <li>Pappas PG, et al. MSG-15 Pharmacokinetic, Adverse Events and tolerability data from an open label randomized clinical trial comparing oral SUBA-itraconazole to conventional itraconazole for treatment of endemic mycosis. IDWeek 2020, Abstract O-144. ClinicalTrials.gov Identifier: NCT03572049.</li>
                    <li>Prentice AG, Glasmacher A. J Antimicrob Chemother. 2005;56(Suppl 1):i17-i22.</li>
                    <li>TOLSURA® Product Information. Mayne Pharma. Greenville, NC. 12/2018.</li>
                    <li>Mudge S, Burnett BP. Pharmacokinetic Analysis of SUBA™-itraconazole Capsules Compared to Conventional Itraconazole Capsules for a 3-Day Loading Dose Regimen and After 15 Days of Administration. Poster presented (#L0043) at 29th European Congress of Clinical Mi¬crobiology & Infectious Diseases, Amsterdam, Netherlands. April 13-16, 2019.</li>
                    <li>Lindsay J, et al. Antimicrob Agents Chemother. 2018;62(12)e01723-18.</li>
                    <li>Data on File. Clinical study report MPG 017.</li>
                </ul>
            </div>
        </div>
    </div>
</div>
<!-- REFERENCE SECTION START -->
    
<div id="isi" class="section">
    <div class="container pb-100">
        <div class="row">
            <div class="col-md-12">
            <p>Indications and Important <br class="d-block d-lg-none d-md-none">  Safety Information 
                <span class="expand-collapse-isi">
                    <a href="#"><img class="fa fa-plus expand-isi" src="https://awareness.tolsura.com/l/153741/2021-04-12/442dl8/153741/1618221207YVr2k8j6/plus__icon.jpg" alt="plus icon"></a>
                    <a href="#"><img class="fa fa-minus collapse-isi expand-isi" src="https://awareness.tolsura.com/l/153741/2021-04-12/442dkx/153741/1618221206p3dCVT78/minus__icon.jpg" alt="minus icon"></a>
                </span>
                </p>
                <div class="warning-box">
                <p class="mb-0"><strong>BOXED WARNING</strong> <br /><strong>WARNING: CONGESTIVE HEART FAILURE and DRUG INTERACTIONS</strong> </p>
                <ul class="bullet1 mb-1 mt-1">
                <li> » CONGESTIVE HEART FAILURE</li>
                </ul>
            <p class="mb-1 pl-3"><strong>TOLSURA can cause or exacerbate congestive heart failure (CHF). When itraconazole was administered intravenously to healthy human volunteers and dogs, negative inotropic effects were seen. </strong>If signs or symptoms
        of congestive heart failure occur or worsen during administration of TOLSURA, reassess the benefit and risk of
        continuing treatment.</p>
            <ul class="bullet1">
                <li>  » DRUG INTERACTIONS</li>
            </ul>
            <ul class="bullet2">
                <li>Co-administration of certain drugs that are metabolized by human CYP3A4 enzymes are contraindicated with
                    TOLSURA because plasma concentrations of such drugs are increased, which may also increase or prolong both the
                    pharmacologic effects and/or adverse reactions to these drugs.</li>
                <li>Co-administration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and</li>
                <li>Co-administration with eligustat is contraindicated in subjects taking strong or moderate CYP2D6 inhibitors. </li>
                <li>Increased plasma concentrations of some of these drugs caused by co-administration with TOLSURA can lead to QT prolongation and/or ventricular tachyarrhythmias, including occurrences of torsades de pointes, a potentially fatal arrhythmia. </li>
            </ul>
        </div>
            
        </div>
        <div class="col-md-12">
            <p class="mb-0"><strong>Indications and Usage</strong> </p>
            <p >TOLSURA is an azole antifungal indicated for the treatment of the following fungal infections in <strong>immunocompromised and non-immunocompromised</strong> adult patients:</p>           
            <ul class="bullet2 ml-2">
                <li>Blastomycosis, pulmonary and extrapulmonary</li>
                <li>Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and</li>
                <li>Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy </li>
            </ul>
            <p class="mb-0 mb-2 mt-4"><strong>Limitations of Use:</strong></p>
                <p class="mb-0">TOLSURA is not indicated for the treatment of onychomycosis.</p>
                <p class="mb-0">TOLSURA is NOT interchangeable or substitutable with other itraconazole products.</p>
                <p class="mb-0 mb-2 mt-4"><strong>Contraindications</strong></p>
                <p class="mb-0">Co-administration with certain drugs that either affect metabolism of itraconazole or whose metabolism is affected by itraconazole Hypersensitivity to itraconazole</p>            
            <p class="mb-0 mb-2 mt-4"><strong>Warnings and Precautions</strong></p>
            <ul class="bullet2 ml-2">
                <li><strong>Hepatotoxicity:</strong> Serious hepatotoxicity, including liver failure and death, were reported with the use of itraconazole. Discontinue treatment if signs of liver dysfunction occur</li>
                <li><strong>Cardiac Dysrhythmias:</strong> Life-threatening cardiac dysrhythmias and/or sudden death have occurred in patients using certain drugs that are metabolized by human CYP450 enzymes concomitantly with oral itraconazole and/or other CYP3A4 inhibitors.</li>
                <li><strong>Peripheral Neuropathy:</strong> This has been reported in patients on long-term therapy with itraconazole. Monitor and promptly evaluate neurologic symptoms </li>
                <li><strong>Hearing loss:</strong> Reversible or permanent hearing loss has been reported in patients. Discontinue treatment if hearing loss occurs </li>
            </ul>
            <p class="mb-0 mb-2 mt-4"><strong>Adverse Reactions</strong></p>
            <p class="mb-4">Most common adverse reactions (incidence ≥ 1%) are nausea, rash, vomiting, edema, headache, diarrhea, fatigue, fever, pruritus, hypertension, abnormal hepatic function, abdominal pain, dizziness, hypokalemia, anorexia, malaise, decreased libido, somnolence, albuminuria, and impotence.</p>
            <p class="mb-4"><strong>To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at <a href="tel:+18448258500">1-844-825-8500</a> or the FDA at 1-800-FDA-1088 or <a target="_blank" href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program"><u>www.fda.gov/medwatch.</u></a></strong></p>
            <p class="mb-0"><strong>For more information, please see full <a class="underline" target="_blank" href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=306352d1-9d5a-49ad-b72d-893b99546861&audience=professional"><u>Prescribing Information and Patient Information Leaflet.</u> </a></strong></p>
            </div>
        </div>
    </div>
</div>
<!-- ISI BLOCK END -->

<!-- FOOTER START -->
<footer>
    <div class="container">
        <div class="row">
            <div class="col-lg-3">
                <a href="#" class="footer__logo mb-lg-0 mb-4">
                    <img src="assets/img/TOLSURA_DARK_LOGO.png" alt="Tolsura">
                </a>
            </div>
            <div class="col-lg-5">
                <div class="footer__links mb-lg-0 mb-4">
                    <ul>
                        <li><a href="#">HOME</a></li>
                        <li><a href="#">INFECTIONS OVERVIEW</a></li>
                        <li><a href="#">ABOUT TOLSURA</a></li>
                        <li><a href="#">BENEFITS OF TOLSURA</a></li>
                        <li><a href="#">SAFETY</a></li>
                        <li><a href="#">DOSING</a></li>
                        <li><a href="#">SAVINGS</a></li>
                    </ul>
                </div>
            </div>
            <div class="col-lg-4">
                <div class="customer__service mb-4">
                    Customer Service <div class="d-block"><a href="tel:+18003448661">+1 800 344 8661</a></div>
                </div>
                <div class="address mb-4">
                    1240 Sugg Parkway, Greenville, NC 27834
                </div>
                <div class="medical__info mb-lg-3 mb-4">
                    Medical Information & Adverse Drug Events Reporting
                </div>
                <div class="report">
                    To report a suspected adverse reaction from one of our products, please contact Mayne Pharma at <a href="tel:+18448258500">1-844-825-8500</a> or the FDA at <a href="tel:+1800FDA1088">1-800-FDA-1088</a> or <a href="http://www.fda.gov/medwatch" target="_blank" >www.fda.gov/medwatch</a>.
                </div>
            </div>
        </div>
        <div class="footer__bottom pt-150">
            <div class="row">
                <div class="col-12">
                    <div class="social__icon">
                        <ul>
                            <li><a href="#"><img src="assets/img/Icons_brand_twitter.svg" alt="Twitter"></a></li>
                            <li><a href="#"><img src="assets/img/Icons_brand_facebook.svg" alt="Facebook"></a></li>
                        </ul>
                    </div>
                </div>
                <div class="col-12">
                    <div class="footer__copyright">
                        <div class="row">
                            <div class="col-lg-6">
                                <div class="d-flex">
                                    <div class="copyright__text">© 2021 <a href="https://www.maynepharma.com/" target="_blank">Mayne Pharma</a>. All Rights Reserved.</div>
                                    <div class="pm__tool">PM-US-TOL-0002. 01/19</div>
                                </div>
                            </div>
                            <div class="col-lg-6">
                                <ul class="float-lg-right">
                                    <li><a href="https://www.maynepharma.com/privacy-policy/" target="_blank">Privacy Policy</a></li>
                                    <li><a href="https://www.maynepharma.com/terms-and-conditions/" target="_blank">Terms of Use</a></li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>
</footer>
<!-- FOOTER END -->


<!-- JS Script -->
<script src="assets/js/jquery-3.5.1.min.js"></script>
<script src="assets/js/bootstrap.min.js"></script>
<script src="assets/js/lazysizes.min.js"></script>
<script src="assets/js/ls.bgset.min.js"></script>
<script src="assets/js/custom.js"></script>
</body>
</html>
